Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma

Cancer Gene Therapy

Volumn 22, Issue 11, 2015, Pages 530-535

  Najafi, Z ^a   Sharifi, M ^b   Javadi, G ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA 21; MICRORNA; MIRN21 MICRORNA, HUMAN; OLIGONUCLEOTIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; UPREGULATION; CELL PROLIFERATION; CELL SURVIVAL; GENETICS; LIVER TUMOR; RNA STABILITY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDES; RNA STABILITY;

EID: 84947129600     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.51     Document Type: Article

References (41)

1. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34 (suppl 1): D140-D144.
2. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001; 294: 862-864.
3. Tüfekci KU, Meuwissen RLJ, Genç S. The role of microRNAs in biological processes. Yousef M (ed). In: miRNomics: MicroRNA Biology and Computational Analysis. Springer: New York, 2014, pp 15-31.
4. Drakaki A, Iliopoulos D. MicroRNA gene networks in oncogenesis. Curr Genomics 2009; 10: 35.
5. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009; 379: 726-731.
6. Fabbri M, Garzon R, Andreeff M, Kantarjian H, Garcia-Manero G, Calin G. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 2008; 22: 1095-1105.
7. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front Genet 2012; 3: 56.
8. Liu H, Qin H, Chen G, Liang M, Rong J, Yao J et al. Comparative expression profiles of microRNA in left and right atrial appendages from patients with rheumatic mitral valve disease exhibiting sinus rhythm or atrial fibrillation. J Transl Med 2014; 12: 90.
9. Rebane A, Runnel T, Aab A, Maslovskaja J, Rückert B, Zimmermann M et al. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. J Allergy Clin Immunol 2014; 1344: 836-847, e11.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA 2011; 61: 69-90.
11. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15 (Suppl 4): 14-22.
12. Sun J, Lu H, Wang X, Jin H. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. Sci World J 2013; 2013: 924206.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
14. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-And HCV-Associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135.
15. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol 2013; 87: 227-247.
16. Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M et al. The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Hum Pathol 2015; 46: 50-57.
17. Asangani I, Rasheed S, Nikolova D, Leupold J, Colburn N, Post S et al. MicroRNA-21 (miR-21) post-Dranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136.
18. Maachani UB, Tandle A, Shankavaram U, Kramp T, Camphausen K. Modulation of miR-21 signaling by MPS1 in human glioblastoma. Oncotarget (e-pub ahead of print 15 May 2015).
19. Croce CM, Fabbri M. Methods and compositions related to MiR-21 & MiR-29a, exosome inhibition, and cancer metastasis. In: US Patent 20,140,323,553, 2014.
20. Dong C, Ji M, Ji C. microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Therapy 2009; 8: 200-205.
21. Saunders MA, Lim LP. (micro) Genomic medicine: microRNAs as therapeutics and biomarkers. RNA Biol 2009; 6: 324.
22. Trang P, Weidhaas J, Slack F. MicroRNAs as potential cancer therapeutics. Oncogene 2008; 27: S52-S57.
23. Orum H. Locked nucleic acids as MicroRNA therapeutics. MicroRNAs Med 2014: 663-672.
24. Burdick AD, Sciabola S, Mantena SR, Hollingshead BD, Stanton R, Warneke JA et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res 2014; 42: 4882-4891.
25. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137-141.
26. Di Martino MT, Cantafio MEG, Gullá A, Altomare E, Morelli E, Amodio N et al. In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor. Cancer Res 2014; 74 (19 Suppl): 4789-4789.
27. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
28. George G, Mittal RD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem 2010; 25: 4-14.
29. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147.
30. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033.
31. Si M, Zhu S, Wu H, Lu Z, Wu F, Mo Y. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803.
32. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
33. Barbano R, Pasculli B, Palumbo O, Galasso M, Volinia S, D'Angelo V et al. A miRNA signature distinguishing low-grade and high-grade gliomas shows miR-21 and 210 as promising biomarkers of aggressive phenotype and prognosis. Cancer Res 2014; 74 (19 Suppl): 1479-1479.
34. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
35. Reddy SDN, Gajula RP, Pakala SB, Kumar R. MicroRNAs and cancer therapy. Cancer Biol Therapy 2010; 9: 479-482.
36. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285: 116-126.
37. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
38. Dai X, Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev 2015; 81: 184-197.
39. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. MicroRNA targeted therapy for overcoming drug resistance, reversal of EMT and elimination of cancer stem cells in prostate and pancreatic cancer. Sarkar FH (ed). In: MicroRNA Targeted Cancer Therapy. Springer: Switzerland, 2014, pp 199-217.
40. Garofalo M, Di Leva G, M Croce C. MicroRNAs as anti-cancer therapy. Curr Pharm Des 2014; 20: 5328-5335.
41. Bai S, Nasser MW, Wang B, Hsu S-H, Datta J, Kutay H et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027.